Tenderwize
Retour à la recherche

Rivaroxaban (ATC B01AF01)

AOK - Die Gesundheitskasse in Hessen·Bad Homburg, Germany·Deadline Feb 01, 2027 · 109 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

5/100

Score d'opportunité

High riskLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

5 / 100

Complexité

20 / 100

Facteurs de risque

The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...

No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK - Die Gesundheitskasse in Hessen
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Feb 01, 2027

Aperçu

Weak opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclude non-exclusive discount agreements for finished medicinal products (Open House model).
  • Only specified active ingredient: Rivaroxaban (ATC B01AF01) – but this lot is cancelled.
Afficher le résumé complet

This is an Open House model (non-exclusive discount agreements under §130a Abs. 8 SGB V) for finished medicinal products. The only listed lot (Rivaroxaban) is being cancelled as of 30 September 2025, with no new contracts. The overall submission deadline is 1 February 2027, but electronic submission is not allowed (email submission mentioned in XML notice). No estimated value, award criteria, or detailed eligibility criteria are provided. The tender appears to be a correction of a previous notice.

Risques

The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...

No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Contractors must be able to supply finished medicinal products with specified active ingredients.
  • Agreements are non-exclusive and follow the Open House model.
  • Contracts can be terminated early if AOK Hessen conducts an exclusive tender for the same active ingredients.

Critères d'attribution

Lot 1

No award criteria specified for this lot.

Acheteur

Localisation

Bad Homburg, DEU

Site web

www.aok.de

Identifiant

DE114110216

Activité

Health

Lots (1)

LOT-0001

Rivaroxaban (ATC B01AF01)

This lot is cancelled as of 30 September 2025. No contracts will be concluded. A new procedure will be published. Scope: pharmaceutical product Rivaroxaban.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Mar 2025 - Mar 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified for this lot.

Détails de la procédure

Date de publication
20 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
546345-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30